Prostate-cancer-specific PAP (prostatic acid phosphatase)-GM-CSF (granulocyte-macrophage colony-stimulating factor)-IL-6 (interluekin-6) genetic recombinant fusion protein and preparation method thereof

Abstract

The invention relates to preparation of a genetic recombinant protein, in particular to a prostate-cancer-specific PAP (prostatic acid phosphatase)-GM-CSF (granulocyte-macrophage colony-stimulating factor)-IL-6 (interluekin-6) genetic recombinant fusion protein and a preparation method thereof. The preparation method comprises steps of design and synthesis of primers, gene amplification and sequencing, construction of a recombinant vector pc DNA3.1-PAP-GM-CSF-IL-6, screening and identification of the recombinant vector pc DNA3.1-PAP-GM-CSF-IL-6, transfection of the recombinant vector pc DNA3.1-PAP-GM-CSF-IL-6 into an HEK293 cell line, as well as expression, separation, purification, concentration and determination of the PAP-GM-CSF-IL-6 recombinant fusion protein in the HEK293 cell line.

Description

technical field [0001] The invention relates to the preparation of a gene recombinant protein, in particular to the preparation method of the prostate cancer-specific PAP-GM-CSF-IL-6 gene recombinant fusion protein. Background technique [0002] Among the malignant tumors with high incidence in men in Western countries, prostate cancer has the second highest mortality rate of cancer mortality, second only to lung cancer. Since the 1990s, experimental research on prostate cancer has been paid attention to and carried out rapidly in my country. However, the pathogenesis of advanced prostate cancer and androgen-independent prostate cancer is poorly understood, and there is no effective treatment. Methods, the current research is still in the exploratory stage, and needs to be further explored through a large number of in vivo and in vitro experiments. In December 2008, the U.S. FDA officially approved DC-induced tumor immunotherapy for clinical application. There are a variety ...

AI Technical Summary

Problems solved by technology

Since the 1990s, experimental research on prostate cancer has been paid attention to and carried out rapidly in my country. However, the pathogenesis of advanced prostate cancer and androgen-independent prostate cancer is poorly understood, and there is no effective treatment. method, the current research is still in the exploratory stage, and needs to be further explored through a large number of in vivo and in vitro experiments

In December 2008, the U.S. FDA officially approved DC-induced tumor immunotherapy for clinical application. There are a variety of tumor antigens currently used, including tumor cell lysates, tumor-associated whole antigens, protein peptides, and protein single peptides. Most of the DC vaccine preparation methods use tumor tissue blocks or cancer-related proteins as targeting substances, which have low loading efficiency, low targeting, and poor specificity

Images